Key takeaways for New Mexico
- • Wegovy is the FIRST weight-loss GLP-1 with an MACE-reduction indication (Mar 2024).
- • Ozempic carries a CV indication in T2D adults with established CVD.
- • SELECT showed 20% MACE reduction over roughly 3.3 years on Wegovy.
- • Centennial Care coverage rules apply for Cardiovascular Risk Reduction patients in New Mexico — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Cardiovascular Risk Reduction
Multiple GLP-1 drugs have FDA-approved cardiovascular indications. In March 2024, Wegovy became the first weight-loss drug approved to reduce risk of major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal MI, non-fatal stroke — in adults with established CVD and obesity/overweight. Ozempic carries an MACE-reduction indication in T2D adults with established CVD. Evidence grade: A (large outcomes trials). Trulicity (dulaglutide) has a similar T2D CV indication via REWIND. These indications are based on dedicated CV outcomes trials, not extrapolation.
New Mexico-specific context
New Mexico has telehealth access concentrated in Albuquerque, Las Cruces, Rio Rancho metros, with additional reach to Santa Fe and Roswell. University of New Mexico Health, Presbyterian Healthcare Services is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.nmhealth.org.
New Mexicotelehealth & pricing rules
- • New Mexico permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • New Mexico allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in New Mexico: (compounded options often lower, brand higher).